- Updates in the Management of CIDP – CE Whitepaper
- Module 1: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Introduction and Overview
- Module 2: Initiating treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)
- Module 3: Maintenance and long-term treatment with IgG in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
- Launch: October 18, 2023 – Expiration: October 18, 2024
- Jointly provided by Partners for Advancing Clinical Education (PACE) and Ig National Society, Inc. (IgNS)
- This activity is supported by an independent educational grant from Grifols
Target Audience
This activity is intended for pharmacists and nurses who care for patients with CIDP.
Educational Objectives
Upon completion of this activity, participants should be able to:
Module 1:
- Describe the diagnostic triad used for evaluating patients
- List three factors of consideration in determining to initiate therapy
- Describe two characteristics of CIDP
Module 2:
- Describe the role of auto-antibodies in CIDP
- Describe three treatment options for CIDP
- Discuss three techniques to evaluate clinical response to Ig therapy
Module 3:
- Describe the four variatns of CIDP
- Discuss the risks and benefits of CIDP treatment modalities
- Compare and contrast IVIG vc SCIG in managing CIDP
Faculty and Disclosure of Conflicts of Interest
PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:
Faculty
Dr. Richard Lewis
Professor of Neurology
Cedar Sinai Medical Center
Conflicts of Interest
Consultant/Advisor/Speaker: Annexon, Argenx, Boehringer Ingelheim, CSL Behring, Grifols, Janssen, Pfizer, Roche, Sanofi, Takeda, Immunovant, Dianthus
Faculty
Dr. Mazen Dimachkie
Professor of Neurology
University of Kansas Medical Center
Conflicts of Interest
Consultant: Abcuro, Amazentis/Vandria, Dianthis, ArgenX, Astellas, Catalyst, Cello, CNSA, Covance/Labcorp, CSL-Behring, Dianthus, EcoR1, EMD Serono/Merck, Janssen, Kezar, MDA, Medlink, Momenta, NuFactor, Octapharma, Priovant, RaPharma/UCB, Roivant Sciences Inc, Sanofi Genzyme, Shire Takeda, Scholar Rock, Spark Therapeutics, TACT, Abata/Third Rock, UCB Biopharma.
Research Grants/Contracts/Educational Grants: Alexion, Alnylam Pharmaceuticals, Amicus, Biomarin, Bristol-Myers Squibb, Catalyst, Corbus, CSL-Behring, FDA/OOPD, GlaxoSmithKline, Genentech, Grifols, Kezar, Mitsubishi Tanabe Pharma, MDA, NIH, Novartis, Octapharma, Orphazyme, Ra Pharma/UCB, Sanofi Genzyme, Sarepta Therapeutics, Shire Takeda, Spark Therapeutics, The Myositis Association, UCB Biopharma / RaPharma, Viromed/Healixmith & TMA.
Faculty
Jeffrey Rosenfeld , MD, PhD
Professor of Neurology
Loma Linda University Health
Conflicts of Interest
Consultant/Advisor/Speaker: Argenx, Amylyx, NeuroSense, ML Bio, MTPA, Catalyst
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and IgNS. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hours.
Pharmacy Continuing Education
PACE designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008073-9999-23-273-H01-P)
Type of Activity: Knowledge
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions for Credit
Participation in this self-study activity should be completed in approximately 1.0 hour. To successfully complete this activity and receive CE credit, learners must follow these steps during the period from 10/18/2023 through 10/18/2024:
- Review the objectives and disclosures
- Study the educational content
- Complete the activity evaluation
For Pharmacists: Upon completing the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.
For additional information about the accreditation of this activity, please visit https://partnersed.com